Search Result

Results for "

leukotriene receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Leukotriene Receptor (89) 17β-HSD (1) Apoptosis (3) c-Fms (1) Calcium Channel (1) COX (2) Drug Metabolite (1) Endogenous Metabolite (5) FAP (1) G protein-coupled Bile Acid Receptor 1 (1) iGluR (1) Isotope-Labeled Compounds (8) Lipoxygenase (3) LPL Receptor (2) Opioid Receptor (1) P-glycoprotein (2) Phosphatase (1) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (2) Reference Standards (6) TNF Receptor (2)
By Research Areas:	Cancer (16) Cardiovascular Disease (5) Endocrinology (3) Inflammation/Immunology (88) Metabolic Disease (4) Neurological Disease (2)

By Targets:

Leukotriene Receptor (89)

17β-HSD (1)

Apoptosis (3)

c-Fms (1)

Calcium Channel (1)

COX (2)

Drug Metabolite (1)

Endogenous Metabolite (5)

FAP (1)

G protein-coupled Bile Acid Receptor 1 (1)

iGluR (1)

Isotope-Labeled Compounds (8)

Lipoxygenase (3)

LPL Receptor (2)

Opioid Receptor (1)

P-glycoprotein (2)

Phosphatase (1)

Platelet-activating Factor Receptor (PAFR) (1)

Prostaglandin Receptor (2)

Reference Standards (6)

TNF Receptor (2)

By Research Areas:

Cancer (16)

Cardiovascular Disease (5)

Endocrinology (3)

Inflammation/Immunology (88)

Metabolic Disease (4)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Leukotriene Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19989

MK-571 Maximum Cited Publications 33 Publications Verification L-660711	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) is an orally active, potent and selective competitive **leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1)** inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-17492

Zafirlukast 3 Publications Verification ICI 204219	Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) *receptor* antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-13315

Montelukast sodium 10+ Cited Publications MK0476	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast sodium (MK0476) is a potent, selective and orally active antagonist of *cysteinyl leukotriene* receptor 1 (CysLT₁)**. Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast sodium decreases eosinophil infiltration into the asthmatic airways. Montelukast sodium can also be used for COVID-19 research .

HY-13315A

Montelukast 10+ Cited Publications MK0476 free base	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of *cysteinyl leukotriene* receptor 1 (CysLT₁)**. Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-19989A

MK-571 sodium Maximum Cited Publications 33 Publications Verification L-660711 sodium	P-glycoprotein LPL Receptor Leukotriene Receptor	Inflammation/Immunology
MK-571 (L-660711) sodium is an orally active, potent and selective competitive **leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1)**. MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .

HY-16780

Gemilukast ONO-6950	Leukotriene Receptor	Inflammation/Immunology
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT₁ and CysLT₂) antagonist, with IC₅₀s of 1.7, 25 nM for human CysLT₁ and CysLT₂, respectively. Gemilukast is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-107609

BAY-u 9773	Leukotriene Receptor	Inflammation/Immunology Endocrinology
BAY-u 9773 is a selective cysteinyl-leukotriene receptor antagonist. BAY-u 9773 competitively antagonizes cysteinyl-leukotriene-induced contractions at typical and atypical cysteinyl-leukotriene receptors with comparable activity. BAY-u 9773 can be used for the research of trichomoniasis .

HY-19193

CP-105696 4 Publications Verification Pfizer 105696	Leukotriene Receptor	Inflammation/Immunology
CP-105696 is a potent and selective Leukotriene B₄ Receptor antagonist, with an IC₅₀ of 8.42 nM.

HY-13628

Etalocib 2 Publications Verification LY293111; VML 295	Leukotriene Receptor Apoptosis	Inflammation/Immunology Cancer
Etalocib (LY293111), an orally active **leukotriene B₄ receptor antagonist, inhibits the binding of [ ³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀** of 20 nM. Etalocib (LY293111) induces apoptosis .

HY-112737

LY223982 CGS23131; SKF107324	Leukotriene Receptor	Inflammation/Immunology
LY223982 is a potent and specific inhibitor of **leukotriene B4 receptor, with an IC₅₀** of 13.2 nM against [ ³H]LTB4 binding to LTB4 receptor.

HY-116326

BayCysLT2	Leukotriene Receptor	Inflammation/Immunology
BayCysLT2, an isophthalic acid derivative, is a selective and potent cysteinyl leukotriene 2 (CysLT2) receptor antagonist with an IC₅₀ value of 53 nM. BayCysLT2 inhibits calcium mobilization induced by leukotriene D4 in HEK293 cells expressing human CysLT2 receptors. BayCysLT2 reverses LTC4-induced increases in coronary artery perfusion pressure and decreases in contractility in isolated perfused guinea pig hearts .

HY-122124

CAY10583	Leukotriene Receptor	Inflammation/Immunology
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds .

HY-76511

Verlukast MK-679; L 668019	Leukotriene Receptor	Inflammation/Immunology
Verlukast is a potent, selective, and orally active antagonist of **leukotriene receptor**. Verlukast has the potential for the research of asthma .

HY-108396

γ-Linolenic acid ethyl ester Ethyl γ-linolenate	Leukotriene Receptor	Inflammation/Immunology
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B₄ receptor 4 (LTB₄) antagonist .

HY-114641A

BIIL-260 hydrochloride 1 Publications Verification	Leukotriene Receptor	Inflammation/Immunology
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB₄ antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with K_i values of 1.7 nM .

HY-119442

Quininib 1 Publications Verification	Leukotriene Receptor	Cardiovascular Disease
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC₅₀s of 1.2 and 52 μM for CysLT₁R and CysLT₂R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents .

HY-113483

20-Carboxy-Leukotriene B4 20-COOH LTB4	Drug Metabolite Leukotriene Receptor	Metabolic Disease
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .

HY-U00252

ONO4057 ONO-LB457	Leukotriene Receptor	Inflammation/Immunology
ONO4057 is a **Leukotriene B₄ receptor antagonist, with an IC₅₀** of 0.7±0.3 μM.

HY-14938

Tipelukast KCA 757; MN 001	Leukotriene Receptor	Inflammation/Immunology
Tipelukast (KCA 757) is a sulfidopeptide **leukotriene receptor** antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.

HY-156978

Ritolukast Wy-48252	Leukotriene Receptor	Others
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD₄/E₄) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD₄ in guinea pigs, with an ID₅₀ of 0.5mg/kg .

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe L-BOC2	Leukotriene Receptor	Inflammation/Immunology
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .

HY-107607

FPL-55712 free base	Leukotriene Receptor	Inflammation/Immunology
FPL-55712 free base is a **leukotriene receptor antagonist. FPL-55712 free base is also an antagonist of slow reacting substance of anaphylaxis (SRS-A). FPL-55712 free base inhibits leukotriene-induced bronchoconstriction .**

HY-112532

REV 5901	Leukotriene Receptor Lipoxygenase	Inflammation/Immunology Cancer
REV 5901 is a competitive and orally active antagonist of **leukotriene receptor, with a K_i of 0.7 μM. REV 5901 is also a 5-lipoxygenase** inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma .

HY-112742

CP-195543	Leukotriene Receptor	Inflammation/Immunology
CP-195543 is a potent, selective and orally active **leukotriene B4 (LTB4) receptor antagonist with IC₅₀**s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .

HY-176921

ONO-2570366	Leukotriene Receptor	Inflammation/Immunology
ONO-2570366 (Compound 11a) is an antagonist of the cysteinyl leukotriene receptors CysLT1R and CysLT2R (IC₅₀ = 14 nM). ONO-2570366 inhibits the binding of LTD₄receptor conformation, thereby preventing the Gq signaling pathway mediated by receptor activation. ONO-2570366 can be used for the researches of inflammation and immunology, such as asthma .

HY-147086

CAY10789	Leukotriene Receptor G protein-coupled Bile Acid Receptor 1 TNF Receptor	Metabolic Disease Inflammation/Immunology
CAY10789 is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC₅₀=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC₅₀=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .

HY-165155

CysLT1 receptor antagonist-1	Leukotriene Receptor	Inflammation/Immunology
CysLT1 receptor antagonist-1 (Compound 4) is an antagonist for *cysteinyl leukotriene* receptor 1 (CysLT1R) with an IC₅₀** of 3.9 μM. CysLT1 receptor antagonist-1 exhibits weak agonist activity against *G-protein-coupled bile acid receptor* 1 (GPBAR1*) with an efficact of 23% at 10 μM. CysLT1 receptor* antagonist-1 can be used for asthma and allergic diseases researchs .

HY-17492R

Zafirlukast (Standard) ICI 204219 (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology Cancer
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) *receptor* antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-176920

BRI-12349	Leukotriene Receptor	Inflammation/Immunology
BRI-12349 (Compound 50) is a dual antagonist of CysLT1R/CysLT2R with K_i values of 1.03 and 6.46 μM. BRI-12349 can inhibit the generation of IP₁ induced by LTD₄ (the main ligand of CysLTs). BRI-12349 can be used for the research of immunology and inflammation, such as asthma .

HY-13315B

Montelukast dicyclohexylamine MK0476 dicyclohexylamine	Leukotriene Receptor	Inflammation/Immunology Cancer
Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of *cysteinyl leukotriene* receptor 1 (CysLT₁)**. Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research .

HY-13315AR

Montelukast (Standard) MK0476 free base (Standard)	Reference Standards Leukotriene Receptor	Inflammation/Immunology
Montelukast (Standard) is the analytical standard of Montelukast. This product is intended for research and analytical applications. Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of *cysteinyl leukotriene* receptor 1 (CysLT₁)**. Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research .

HY-19395

MEN-91507	Leukotriene Receptor	Inflammation/Immunology
MEN-91507 is an orally activecysteinyl leukotriene receptor 1 (CysLTR1) receptor antagonist. MEN-91507 behaves as insurmountable antagonist of Leukotriene D4 (HY-113456)-induced calcium transients, with a pK_b of 10.25. MEN-91507 can inhibit Leukotriene D4-induced bronchoconstriction and microvascular leakage in guinea-pigs. MEN-91507 can be used for the researches of inflammation, immunology .

HY-U00253

KP496	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
KP496 is a selective, dual antagonist for **Leukotriene D4 receptor** and Thromboxane A2 receptor.

HY-122149

L-648051	Leukotriene Receptor	Cardiovascular Disease
L-648051 is a leukotriene D4 receptor (LTD4) antagonist. L-648051 plays an important role in arrhythmias .

HY-U00072

RS-601	Leukotriene Receptor Prostaglandin Receptor	Inflammation/Immunology Endocrinology
RS-601 is a novel leukotriene D4 (LTD4)/thromboxane A2 (TxA2) dual receptor antagonist, with antiasthmatic activities.

HY-76511S

Verlukast-d6 MK-679-d₆; L 668019-d₆	Isotope-Labeled Compounds Leukotriene Receptor	Inflammation/Immunology
Verlukast-d₆ is a deuterium labeled Verlukast. Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma .

HY-101731

CP-96021 hydrochloride	Leukotriene Receptor	Inflammation/Immunology
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with K_i values of 34 nM and 37 nM, respectively .

HY-105483

MDL 43291	Leukotriene Receptor	Inflammation/Immunology
MDL 43291 is a competitive *leukotriene* (LT) receptor antagonist. MDL 43291 antagonize LTD4 and LTE4 with pA2 of 6.7. MDL 43291 does not antagonize histamine, carbachol or substance P. MDL 43291 can be used for the researches of inflammation and immunology, such as asthma .

HY-112740

SC-53228	Leukotriene Receptor	Inflammation/Immunology
SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis .

HY-112741

SB-209247 1 Publications Verification	Leukotriene Receptor	Inflammation/Immunology
SB-209247 is a selective, high affinity and orally active **leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca ²⁺ mobilization with an IC₅₀** of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .

HY-13315S1

Montelukast-d6 sodium MK0476-d₆	Leukotriene Receptor	Inflammation/Immunology
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-115500

PL265	Endogenous Metabolite Opioid Receptor Leukotriene Receptor	Neurological Disease Inflammation/Immunology
PL265 is an orally active dual enkephalinase inhibitor. PL265 is a prodrug of PL254, which can simultaneously and efficiently inhibit neutral endopeptidase (Neprilysin) and Aminopeptidase N. PL265 can effectively protect and significantly increase the local concentration of enkephalins (such as Met-Enkephalin and Leu-Enkephalin) released by cells at the pain or inflammation sites, thereby activating μ and δ opioid receptors to produce a potent analgesic effect. PL254 can also inhibit leukotriene A4 hydrolase (LTA4H), which may contribute to its additional anti-inflammatory effect by reducing the production of pro-inflammatory mediator leukotriene B4 (LTB4). PL265 can be used in non-addictive chronic pain research .

HY-112736

RG 14893	Leukotriene Receptor	Inflammation/Immunology
RG 14893 is a high affinity, competitive, orally active **leukotriene B4 receptor** antagonist .

HY-118958

Ablukast Ro 23-3544	Leukotriene Receptor	Inflammation/Immunology
Ablukast (Ro 23-3544) is a specific and active **leukotriene receptor** antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction . Ablukast is LTD4 receptor antagonist .

HY-105426

L-695499	Leukotriene Receptor	Inflammation/Immunology
L-695499 is a potent and orally active **leukotriene D4 receptor** antagonist. L-695499 can be used for the researches of inflammation and immunology .

HY-163101

CP-96021	Platelet-activating Factor Receptor (PAFR) Leukotriene Receptor	Inflammation/Immunology
CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) *receptor* antagonist, featuring a guinea pig LTD4 receptor K_i of 34 nM and a rabbit PAF receptor K_i of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma .

HY-122536

Ricinelaidic acid	Leukotriene Receptor Calcium Channel Endogenous Metabolite	Inflammation/Immunology
Ricinelaidic acid, a 12-hydroxy fatty acid，is a **leukotriene B4 (LTB4) receptor antagonist with the K_i of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC₅₀**=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .

HY-131651

Leukotriene B4 ethanolamide LTB4 ethanolamide	Endogenous Metabolite Leukotriene Receptor	Cancer
Leukotriene B4 ethanolamide (LTB4 ethanolamide) is an antagonist and a partial agonist for Leukotriene B4 (LTB4) receptor 1 (BLTR1). Leukotriene B4 ethanolamide ameliorates the tumor progression, which is only asscociated with inflammation .

HY-U00263

LY210073	Leukotriene Receptor	Inflammation/Immunology
LY210073 is a Leukotriene B₄ (LTB₄) receptor antagonist with an IC₅₀ of 6.2 nM.

HY-105221

Masilukast ZD-3523	Leukotriene Receptor	Inflammation/Immunology
Masilukast is an orally administered cysteinyl leukotriene D₄ (LTD₄) receptor antagonist with potential to research asthma.

Cat. No.	Product Name	Target	Research Area

HY-P3318

Boc-Phe-Leu-Phe-Leu-Phe L-BOC2	Leukotriene Receptor	Inflammation/Immunology
Boc-Phe-Leu-Phe-Leu-Phe (Boc-FLFLF) is a N-formyl peptide receptors (FPR) inhibitor. Boc-Phe-Leu-Phe-Leu-Phe abolishes the FMLP-induced release of peptide leukotrienes. Boc-Phe-Leu-Phe-Leu-Phe inhibits the sprouting of human umbilical vein endothelial cell (HUVEC) spheroids mediated by proliferative diabetic retinopathy (PDR) vitreous and vascular endothelial growth factor (VEGF) respectively in a three-dimensional fibrin gel. Boc-Phe-Leu-Phe-Leu-Phe inhibits the anti-inflammatory and antifibrotic effects of Ac2-26 (HY-P1098). Boc-Phe-Leu-Phe-Leu-Phe can be used for the study of immunology .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-112650

12-OxoETE 12-KETE	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Inflammation/Immunology Source Classification	Endogenous Metabolite
12-OxoETE induces a rapid, dose dependent increase of cytoplasmic free calcium via leukotriene B4 receptor or a common activation sequence .

Cat. No.	Product Name	Chemical Structure

HY-76511S

Verlukast-d6
Verlukast-d₆ is a deuterium labeled Verlukast. Verlukast is a potent, selective, and orally active antagonist of leukotriene receptor. Verlukast has the potential for the research of asthma .

HY-13315S1

Montelukast-d6 sodium
Montelukast-d₆ (sodium) is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-W744275

Tipelukast-d6
Tipelukast-d₆ is the deuterium labeled Tipelukast (HY-14938). Tipelukast (KCA 757) is a sulfidopeptide leukotriene receptor antagonist, an orally bioavailable anti-inflammatory agent and used for the treatment of asthma.

HY-17492S

Zafirlukast-d7
Zafirlukast-d₇ is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects .

HY-17492S3

Zafirlukast-d6
Zafirlukast-d₆ is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D₄ (LTD₄) *receptor* antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S2

Zafirlukast-13C,d6
Zafirlukast- ¹³C,d₆ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-17492S1

Zafirlukast-13C,d3
Zafirlukast- ¹³C,d₃ is the ¹³C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.

HY-13315S

Montelukast-d6
Montelukast-d₆ is the deuterium labeled Montelukast (sodium). Montelukast sodium is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (Cysltr1). Montelukast sodium can be used for the reseach of asthma and liver injury. Montelukast sodium also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage .

HY-W744842

γ-Linolenic acid ethyl ester-d5
γ-Linolenic acid ethyl ester-d₅ (Ethyl γ-linolenate-d₅) is the deuterium labeled γ-Linolenic acid ethyl ester (HY-108396). γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks